皮肤T细胞淋巴瘤的免疫治疗进展
摘要
皮肤T细胞淋巴瘤(cutaneous T-cell lymphoma,CTCL)是一组异质性的T细胞来源的恶性肿瘤,以皮肤损害为初发和突出表现.近年来,其发生率和病死率呈上升趋势,严重威胁人类的健康.早期CTCL治疗效果一般较好,但对中晚期CTCL目前尚无有效的治疗方法.随着对抗肿瘤免疫机制的深入了解和CTCL生物学特性的深入研究,免疫治疗已逐渐成为CTCL临床上重要而有效的辅助治疗手段.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2005年第10期654-657,共4页
Chinese Journal of Dermatology
参考文献26
-
1Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome: regulation by interferon alfa and interleukin 12. J Am Acad Dermatol, 2001, 44: 28-32.
-
2Tsimberidou AM, Giles F, Romaguera J,et al. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer,2004, 100: 574-580.
-
3McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol, 2004, 50: 375-379.
-
4Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs,2001, 15: 419-429.
-
5Wysocka M, Zaki MH, French LE, et al.Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood, 2002, 100: 3287-3294.
-
6Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood,1999, 94:902-908.
-
7Rook AH, Zaki MH, Wysocka M, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci, 2001,941: 177-184.
-
8Marolleau JP, Baccard M, Flageul B, et al.High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol, 1995, 131: 574-579.
-
9Olsen E, Duvic M, Frankel A, et al. Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol,2001, 19: 376-388.
-
10Buggins AG, Mufti GJ, Salisbury J, et al.Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 2002,100: 1715-1720.
-
1韩克强,吴娅利,梁平.光动力疗法治疗肝癌的进展[J].中国激光医学杂志,2009,18(6):391-394.
-
2顾援农.免疫与儿童白血病初探[J].卫生职业教育,2003,21(8):137-138.
-
3张丹,杨成章.肿瘤免疫治疗研究进展[J].临床耳鼻咽喉科杂志,2003,17(3):189-191.
-
4周非凡,邢达,宋盛,陈伟.HSP70调控PDT诱导的肿瘤免疫机制[J].生物物理学报,2009,25(S1):143-143.
-
5杨冬.慢性粒细胞白血病的免疫治疗[J].国外医学（内科学分册）,2001,28(6):260-262.
-
6刘超,吴世凯.放疗联合免疫治疗的抗肿瘤免疫机制研究进展[J].军事医学,2016,40(4):353-355. 被引量：4
-
7刘洪俊,蔡新力,张祖煌.大肠癌癌组织及癌旁组织中MHC-I类分子的表达及意义[J].山东医药,2002,42(18):45-46.
-
8叶栋,沈志森.人抗原R在肿瘤诊断治疗中的研究进展[J].医学综述,2010,16(3):366-368. 被引量：3
-
9贾勇士,林白桦.中医药治疗老年肿瘤的机理研究[J].中华中医药学刊,2012,30(2):439-440. 被引量：2
-
10李莹,袁卫如,郑捷,沈小雁.非化疗和化疗治疗皮肤T细胞淋巴瘤的临床疗效比较[J].临床皮肤科杂志,2008,37(2):91-93. 被引量：4
